| General Information | |
|---|---|
| ZINC ID | ZINC000040874846 |
| Molecular Weight (Da) | 474 |
| SMILES | O=C(NC1CCCCC1)C(=O)N1CCN([C@@H](c2ccc(Cl)cc2)c2ccccc2Cl)CC1 |
| Molecular Formula | C25Cl2N3O2 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 128.342 |
| HBA | 2 |
| HBD | 1 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 32 |
| LogP | 5.274 |
| Activity (Ki) in nM | 223.872 |
| Polar Surface Area (PSA) | 52.65 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | + |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 1.10582983 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 12 |
| Fraction csp3 | 0.44 |
| Ilogp | 4.42 |
| Xlogp3 | 5.5 |
| Wlogp | 3.59 |
| Mlogp | 3.58 |
| Silicos-it log p | 4.59 |
| Consensus log p | 4.34 |
| Esol log s | -6.06 |
| Esol solubility (mg/ml) | 0.000411 |
| Esol solubility (mol/l) | 0.00000086 |
| Esol class | Poorly sol |
| Ali log s | -6.36 |
| Ali solubility (mg/ml) | 0.000205 |
| Ali solubility (mol/l) | 0.00000043 |
| Ali class | Poorly sol |
| Silicos-it logsw | -7.21 |
| Silicos-it solubility (mg/ml) | 0.0000291 |
| Silicos-it solubility (mol/l) | 6.14E-08 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.29 |
| Lipinski number of violations | 0 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 1 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.45 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -4.986 |
| Logd | 4.285 |
| Logp | 4.837 |
| F (20%) | 0.005 |
| F (30%) | 0.006 |
| Mdck | - |
| Ppb | 96.47% |
| Vdss | 1.869 |
| Fu | 1.22% |
| Cyp1a2-inh | 0.15 |
| Cyp1a2-sub | 0.797 |
| Cyp2c19-inh | 0.905 |
| Cyp2c19-sub | 0.811 |
| Cl | 3.594 |
| T12 | 0.014 |
| H-ht | 0.964 |
| Dili | 0.535 |
| Roa | 0.509 |
| Fdamdd | 0.682 |
| Skinsen | 0.064 |
| Ec | 0.003 |
| Ei | 0.008 |
| Respiratory | 0.155 |
| Bcf | 0.834 |
| Igc50 | 4.457 |
| Lc50 | 5.617 |
| Lc50dm | 3.919 |
| Nr-ar | 0.061 |
| Nr-ar-lbd | 0.004 |
| Nr-ahr | 0.091 |
| Nr-aromatase | 0.653 |
| Nr-er | 0.272 |
| Nr-er-lbd | 0.017 |
| Nr-ppar-gamma | 0.008 |
| Sr-are | 0.521 |
| Sr-atad5 | 0.005 |
| Sr-hse | 0.093 |
| Sr-mmp | 0.501 |
| Sr-p53 | 0.748 |
| Vol | 466.631 |
| Dense | 1.014 |
| Flex | 0.269 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 2 |
| Qed | 0.655 |
| Synth | 2.73 |
| Fsp3 | 0.44 |
| Mce-18 | 78.222 |
| Natural product-likeness | -1.44 |
| Alarm nmr | 0 |
| Bms | 1 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |